146 related articles for article (PubMed ID: 33825125)
1. CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.
Doehn JM; Tabeling C; Biesen R; Saccomanno J; Madlung E; Pappe E; Gabriel F; Kurth F; Meisel C; Corman VM; Hanitsch LG; Treskatsch S; Heim K; Stegemann MS; Ruwwe-Glösenkamp C; Müller-Redetzky HC; Uhrig A; Somasundaram R; Spies C; von Bernuth H; Hofmann J; Drosten C; Suttorp N; Witzenrath M; Sander LE; Hübner RH
Infection; 2021 Aug; 49(4):757-762. PubMed ID: 33825125
[TBL] [Abstract][Full Text] [Related]
2. Monocyte CD169 expression in COVID-19 patients upon intensive care unit admission.
Ortillon M; Coudereau R; Cour M; Rimmelé T; Godignon M; Gossez M; Yonis H; Argaud L; Lukaszewicz AC; Venet F; Monneret G
Cytometry A; 2021 May; 99(5):466-471. PubMed ID: 33547747
[TBL] [Abstract][Full Text] [Related]
3. Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019.
Bedin AS; Makinson A; Picot MC; Mennechet F; Malergue F; Pisoni A; Nyiramigisha E; Montagnier L; Bollore K; Debiesse S; Morquin D; Veyrenche N; Renault C; Foulongne V; Bret C; Bourdin A; Le Moing V; Van de Perre P; Tuaillon E
J Infect Dis; 2021 Feb; 223(4):562-567. PubMed ID: 33206973
[TBL] [Abstract][Full Text] [Related]
4. CD169 Defines Activated CD14
Affandi AJ; Olesek K; Grabowska J; Nijen Twilhaar MK; Rodríguez E; Saris A; Zwart ES; Nossent EJ; Kalay H; de Kok M; Kazemier G; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Garcia-Vallejo JJ; Storm G; van Kooyk Y; den Haan JMM
Front Immunol; 2021; 12():697840. PubMed ID: 34394090
[TBL] [Abstract][Full Text] [Related]
5. CD169 and CD64 could help differentiate bacterial from CoVID-19 or other viral infections in the Emergency Department.
Bourgoin P; Soliveres T; Barbaresi A; Loundou A; Belkacem IA; Arnoux I; Bernot D; Loosveld M; Morange PE; Michelet P; Malergue F; Markarian T
Cytometry A; 2021 May; 99(5):435-445. PubMed ID: 33491921
[TBL] [Abstract][Full Text] [Related]
6. SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus.
Stuckrad SLV; Klotsche J; Biesen R; Lieber M; Thumfart J; Meisel C; Unterwalder N; Kallinich T
Lupus; 2020 Dec; 29(14):1914-1925. PubMed ID: 33081587
[TBL] [Abstract][Full Text] [Related]
7. Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.
Boumaza A; Gay L; Mezouar S; Bestion E; Diallo AB; Michel M; Desnues B; Raoult D; La Scola B; Halfon P; Vitte J; Olive D; Mege JL
J Infect Dis; 2021 Aug; 224(3):395-406. PubMed ID: 33493287
[TBL] [Abstract][Full Text] [Related]
8. SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients.
Ostendorf L; Dittert P; Biesen R; Duchow A; Stiglbauer V; Ruprecht K; Bellmann-Strobl J; Seelow D; Stenzel W; Niesner RA; Hauser AE; Paul F; Radbruch H
Sci Rep; 2021 May; 11(1):10299. PubMed ID: 33986412
[TBL] [Abstract][Full Text] [Related]
9. A distinct innate immune signature marks progression from mild to severe COVID-19.
Chevrier S; Zurbuchen Y; Cervia C; Adamo S; Raeber ME; de Souza N; Sivapatham S; Jacobs A; Bachli E; Rudiger A; Stüssi-Helbling M; Huber LC; Schaer DJ; Nilsson J; Boyman O; Bodenmiller B
Cell Rep Med; 2021 Jan; 2(1):100166. PubMed ID: 33521697
[TBL] [Abstract][Full Text] [Related]
10. Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype.
Trombetta AC; Farias GB; Gomes AMC; Godinho-Santos A; Rosmaninho P; Conceição CM; Laia J; Santos DF; Almeida ARM; Mota C; Gomes A; Serrano M; Veldhoen M; Sousa AE; Fernandes SM
Front Immunol; 2021; 12():691725. PubMed ID: 34248984
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte Subset Alteration and Monocyte CD4 Expression Reduction in Patients with Severe COVID-19.
Kazancioglu S; Yilmaz FM; Bastug A; Sakallı A; Ozbay BO; Buyuktarakci C; Bodur H; Yilmaz G
Viral Immunol; 2021 Jun; 34(5):342-351. PubMed ID: 33264073
[TBL] [Abstract][Full Text] [Related]
12. Role of the interferons in CD64 and CD169 expressions in whole blood: Relevance in the balance between viral- or bacterial-oriented immune responses.
Bourgoin P; Biéchelé G; Ait Belkacem I; Morange PE; Malergue F
Immun Inflamm Dis; 2020 Mar; 8(1):106-123. PubMed ID: 32031762
[TBL] [Abstract][Full Text] [Related]
13. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study.
Rose T; Grützkau A; Klotsche J; Enghard P; Flechsig A; Keller J; Riemekasten G; Radbruch A; Burmester GR; Dörner T; Hiepe F; Biesen R
Rheumatology (Oxford); 2017 Sep; 56(9):1618-1626. PubMed ID: 28859328
[TBL] [Abstract][Full Text] [Related]
14. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses.
Jalloh S; Olejnik J; Berrigan J; Nisa A; Suder EL; Akiyama H; Lei M; Tyagi S; Bushkin Y; Mühlberger E; Gummuluru S
bioRxiv; 2022 Mar; ():. PubMed ID: 35378756
[TBL] [Abstract][Full Text] [Related]
15. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution.
Ravichandran S; Lee Y; Grubbs G; Coyle EM; Klenow L; Akasaka O; Koga M; Adachi E; Saito M; Nakachi I; Ogura T; Baba R; Ito M; Kiso M; Yasuhara A; Yamada S; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Yamayoshi S; Yotsuyanagi H; Kawaoka Y; Khurana S
Sci Adv; 2021 Mar; 7(10):. PubMed ID: 33674317
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
[TBL] [Abstract][Full Text] [Related]
18. High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.
Lisney AR; Szelinski F; Reiter K; Burmester GR; Rose T; Dörner T
Ann Rheum Dis; 2017 Aug; 76(8):1476-1480. PubMed ID: 28501799
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and roles of severe acute respiratory syndrome coronavirus 2-specific antibodies in patients with different severities of coronavirus 19.
Huang Z; Chen H; Xue M; Huang H; Zheng P; Luo W; Liang X; Sun B; Zhong N
Clin Exp Immunol; 2020 Nov; 202(2):210-219. PubMed ID: 32706417
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals.
Park J; Dean LS; Jiyarom B; Gangcuangco LM; Shah P; Awamura T; Ching LL; Nerurkar VR; Chow DC; Igno F; Shikuma CM; Devendra G
Front Immunol; 2023; 14():1151780. PubMed ID: 37077911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
